<DOC>
	<DOCNO>NCT01120834</DOCNO>
	<brief_summary>This phase I/II study 5-azacitidine combination vorinostat patient relapse refractory DLBCL . Combination therapy methyltransferase inhibitor histone deacetylase inhibitor highly synergistic DLBCL cell , class drug also synergize powerfully standard anti-lymphoma chemotheraputics doxorubicin pre-clinical study . We hypothesize azacytidine + vorinostat combination therapy safe effective select patient relapse refractory DLBCL . We also hypothesize patient demonstrate objective response combination therapy display specific epigenetic signature , biomarker gene classifier generate identify patient likely respond .</brief_summary>
	<brief_title>Study 5-azacitidine Combination With Vorinostat Patients With Relapsed Refractory Diffuse Large b Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description>Eligible subject biopsy proven relapsed refractory DLBCL , preserve hematologic organ function , either progress follow inappropriate candidate autologous stem cell transplantation . Patients treat 5-azacitidine via subcutaneous administration vorinostat orally four different dose level describe : - Dose level 1 : azacitidine 55 mg/m2 day 1-5 oral vorinostat 300 mg BID Days 1-7 . - Dose level 2 : azacitidine 75 mg/m2 day 1-5 oral vorinostat 200 mg BID Days 1-7 . - Dose level 3 : azacitidine 55 mg/m2 day 1-5 oral vorinostat 300 mg BID Days 1-14 . - Dose level 4 : azacitidine 75 mg/m2 day 1-5 oral vorinostat 200 mg BID Days 1-14 . Each cycle 28 day patient treat 6 cycle . Up 8 patient enrol dose level . If time 2 patient give cohort experience DLT , enrollment level discontinue . Efficacy assess standard radiographic criterion baseline end treatment determine ORR . Patients follow 2 year disease progression . Tumor sample obtain correlative study baseline core needle surgical biopsy , additional biopsy perform day 15 cycle 1 pharmacodynamic endpoint .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients must histologically confirm diffuse large B cell lymphoma , relapse resistant prior systemic therapy . Subjects must measurable disease cross sectional imaging least 1.5 cm diameter . Patients relapse follow deem ineligible autologous stem cell transplantation . There limit number prior therapy . Age &gt; = 18 year . ECOG performance status &lt; = 2 . Patients must normal organ marrow function define : ANC &gt; = 1,000/uL platelet &gt; = 75,000//uL total bilirubin &lt; = 2 X upper limit normal AST ( SGOT ) /ALT ( SGPT ) &lt; = 2.5 X upper limit normal Serum creatinine &lt; = 1.5 X upper limit normal ( ULN ) Women childbearing potential must negative serum pregnancy test prior treatment The effect investigational agent develop human fetus recommend therapeutic dos unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . A woman become pregnant participate study must withdraw study immediately . Ability understand willingness sign write informed consent document . Prior allogeneic transplant Patients may receive investigational agent . Patients may previously receive antilymphoma therapy HDAC inhibitor ( .e.g . Depsipeptide , MS275 , LAQ824 , PXD101 , valproic acid ) . Patients receive HDAC inhibitor another indication epilepsy may enroll 30day washout period Patients know active CNS lymphoma . Subjects previous CNS lymphoma treat chemotherapy , radiotherapy surgery remain asymptomatic 90 day ( 3 month ) demonstrate , CNS lymphoma , show lumbar puncture , CT scan MRI , eligible.. Patients know hypersensitivity azacytidine , vorinostat mannitol . Patients currently active second malignancy . Uncontrolled illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . QTc interval &gt; 0.470 . Consider discontinuation medication prolong QTc interval eliminate exclusion medically appropriate . Pregnant lactate woman exclude study risk unborn fetus potential risk nurse infant unknown .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>diffuse large b cell lymphoma</keyword>
</DOC>